Long Teng , Ling Luo , Yanhong Sun , Wei Wang , Zhi Dong , Xiaopei Cao , Junzhao Ye , Bihui Zhong
{"title":"应用负荷后1小时血糖诊断标准显示潜在MASLD的高进展风险。","authors":"Long Teng , Ling Luo , Yanhong Sun , Wei Wang , Zhi Dong , Xiaopei Cao , Junzhao Ye , Bihui Zhong","doi":"10.1016/j.diabres.2024.111973","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Recently, a 1-h PG value of ≥ 8.6 mmol/L, a more sensitive predictor of diabetes mellitus-related long-term cardiovascular complications than routine glucose markers, has been recommended as an additional diagnostic criterion for diabetes in the International Diabetes Federation Position Statement. However, its value in MASLD remains uncertain.</div></div><div><h3>Methods</h3><div>Consecutive participants with imaging assessments of fatty liver and a 75-g oral glucose tolerance test, including 1154 participants with MASLD, 161 fulfilling the nonalcoholic fatty liver disease but not the MASLD diagnostic criteria (NAFLD-non-MASLD) and 1026 subjects with non-fatty liver, were retrospectively enrolled from June 2009 to May 2024.</div></div><div><h3>Results</h3><div>Patients with MASLD or NAFLD-non-MASLD had higher 1-h PG levels than those with non-fatty liver (<em>p</em> < 0.001). In patients with MASLD or NAFLD-non-MASLD, 1-h PG ≥ 8.6 mmol/L was associated with the risk of moderate-to-severe steatosis (<em>p</em> < 0.001), ALT elevation (<em>p</em> < 0.001), advanced fibrosis (<em>p</em> = 0.03), and cardiovascular diseases (<em>p</em> < 0.001). Furthermore, NAFLD-non-MASLD patients with 1-h PG ≥ 8.6 mmol/L showed a higher prevalence of advanced fibrosis than MASLD patients with or without 1-h PG ≥ 8.6 mmol/L (<em>p</em> < 0.05).</div></div><div><h3>Conclusions</h3><div>NAFLD-non-MASLD patients with 1-h PG ≥ 8.6 mmol/L are still at high risk of poor clinical outcomes. These findings support including 1-h PG ≥ 8.6 mmol/L as a component of the metabolic dysfunction definition.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"220 ","pages":"Article 111973"},"PeriodicalIF":6.1000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Applying 1-hour postload plasma glucose diagnostic criteria reveals high Progressive Risks of potential MASLD\",\"authors\":\"Long Teng , Ling Luo , Yanhong Sun , Wei Wang , Zhi Dong , Xiaopei Cao , Junzhao Ye , Bihui Zhong\",\"doi\":\"10.1016/j.diabres.2024.111973\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Recently, a 1-h PG value of ≥ 8.6 mmol/L, a more sensitive predictor of diabetes mellitus-related long-term cardiovascular complications than routine glucose markers, has been recommended as an additional diagnostic criterion for diabetes in the International Diabetes Federation Position Statement. However, its value in MASLD remains uncertain.</div></div><div><h3>Methods</h3><div>Consecutive participants with imaging assessments of fatty liver and a 75-g oral glucose tolerance test, including 1154 participants with MASLD, 161 fulfilling the nonalcoholic fatty liver disease but not the MASLD diagnostic criteria (NAFLD-non-MASLD) and 1026 subjects with non-fatty liver, were retrospectively enrolled from June 2009 to May 2024.</div></div><div><h3>Results</h3><div>Patients with MASLD or NAFLD-non-MASLD had higher 1-h PG levels than those with non-fatty liver (<em>p</em> < 0.001). In patients with MASLD or NAFLD-non-MASLD, 1-h PG ≥ 8.6 mmol/L was associated with the risk of moderate-to-severe steatosis (<em>p</em> < 0.001), ALT elevation (<em>p</em> < 0.001), advanced fibrosis (<em>p</em> = 0.03), and cardiovascular diseases (<em>p</em> < 0.001). Furthermore, NAFLD-non-MASLD patients with 1-h PG ≥ 8.6 mmol/L showed a higher prevalence of advanced fibrosis than MASLD patients with or without 1-h PG ≥ 8.6 mmol/L (<em>p</em> < 0.05).</div></div><div><h3>Conclusions</h3><div>NAFLD-non-MASLD patients with 1-h PG ≥ 8.6 mmol/L are still at high risk of poor clinical outcomes. These findings support including 1-h PG ≥ 8.6 mmol/L as a component of the metabolic dysfunction definition.</div></div>\",\"PeriodicalId\":11249,\"journal\":{\"name\":\"Diabetes research and clinical practice\",\"volume\":\"220 \",\"pages\":\"Article 111973\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes research and clinical practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0168822724008830\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168822724008830","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Applying 1-hour postload plasma glucose diagnostic criteria reveals high Progressive Risks of potential MASLD
Background
Recently, a 1-h PG value of ≥ 8.6 mmol/L, a more sensitive predictor of diabetes mellitus-related long-term cardiovascular complications than routine glucose markers, has been recommended as an additional diagnostic criterion for diabetes in the International Diabetes Federation Position Statement. However, its value in MASLD remains uncertain.
Methods
Consecutive participants with imaging assessments of fatty liver and a 75-g oral glucose tolerance test, including 1154 participants with MASLD, 161 fulfilling the nonalcoholic fatty liver disease but not the MASLD diagnostic criteria (NAFLD-non-MASLD) and 1026 subjects with non-fatty liver, were retrospectively enrolled from June 2009 to May 2024.
Results
Patients with MASLD or NAFLD-non-MASLD had higher 1-h PG levels than those with non-fatty liver (p < 0.001). In patients with MASLD or NAFLD-non-MASLD, 1-h PG ≥ 8.6 mmol/L was associated with the risk of moderate-to-severe steatosis (p < 0.001), ALT elevation (p < 0.001), advanced fibrosis (p = 0.03), and cardiovascular diseases (p < 0.001). Furthermore, NAFLD-non-MASLD patients with 1-h PG ≥ 8.6 mmol/L showed a higher prevalence of advanced fibrosis than MASLD patients with or without 1-h PG ≥ 8.6 mmol/L (p < 0.05).
Conclusions
NAFLD-non-MASLD patients with 1-h PG ≥ 8.6 mmol/L are still at high risk of poor clinical outcomes. These findings support including 1-h PG ≥ 8.6 mmol/L as a component of the metabolic dysfunction definition.
期刊介绍:
Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.